Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Calcium Homeostasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Calcium Homeostasis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-002280-14 Sponsor Protocol Number: L00006 CP 403 3A Start Date*: 2008-07-18
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ...
    Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006956 Calcium deficiency LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001267-23 Sponsor Protocol Number: PAT13300CCD Start Date*: 2013-06-19
    Sponsor Name:Pharma Patent Kft
    Full Title: Open label multicentric study to evalute the safety and efficacy of CitrokalciumD 300 mg/300 NE tablets in patients assessed deficiency for supplementation of calcium and vitamin D.
    Medical condition: Vitamin D and calcium deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10006956 Calcium deficiency PT
    16.0 10027433 - Metabolism and nutrition disorders 10047626 Vitamin D deficiency PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018553-35 Sponsor Protocol Number: SMF1482 Start Date*: 2010-05-03
    Sponsor Name:Gambro Lundia AB
    Full Title: SMARTCIT - A NOVEL CITRATE BASED ANTICOAGULATION
    Medical condition: Acute renal failure
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10001041 Acute renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000606-36 Sponsor Protocol Number: 84421383 Start Date*: 2008-04-07
    Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Metabolism C
    Full Title: Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001998-25 Sponsor Protocol Number: BLO K025 Start Date*: 2006-09-29
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous...
    Medical condition: Insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blocker
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002269-21 Sponsor Protocol Number: 01.00240 Start Date*: 2013-12-06
    Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto
    Full Title: Metformin in diastolic dysfunction of metabolic syndrome
    Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003645-10 Sponsor Protocol Number: 2014-LSB Start Date*: 2014-11-27
    Sponsor Name:Department of Endocrinology and Internal Medicine
    Full Title: Physiological interactions between the adrenal- and the parathyroid glands described by controlled clinical trials
    Medical condition: Secondary hyperparathyrodism due to Vitamin D deficiency
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004670-28 Sponsor Protocol Number: 2011-AKA Start Date*: 2012-04-25
    Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Internel Medicine (MEA)
    Full Title: Treatment of osteopenia with melatonin: Effects on BMD, muscle strength and quality of life
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000508-40 Sponsor Protocol Number: PAT17-LOADS Start Date*: 2018-06-11
    Sponsor Name:Pharma Patent Kft.
    Full Title: Controlled randomized open label clinical study to compare the efficacy and the safety of the loading dose schedules of Vitamin D3 (colecalciferol) 30,000 IU product in deficient patients
    Medical condition: Vitamin-D deficient patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10047626 Vitamin D deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006692-20 Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) Start Date*: 2007-09-06
    Sponsor Name:St. Vincent Hospital, Medical Department II
    Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study
    Medical condition: Osteoporosis in Men
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005063-34 Sponsor Protocol Number: CL1-11-040 Start Date*: 2009-09-14
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyr...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) BE (Completed) GB (Completed) IT (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-003183-75 Sponsor Protocol Number: 752/11 Start Date*: 2012-01-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: the role of vitamin D supplementation in the prevention of cardiovascular risk factors
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001983-49 Sponsor Protocol Number: UX023-CL205 Start Date*: 2019-10-10
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children from 1 to 4 Years Old with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001511-22 Sponsor Protocol Number: 004 Start Date*: 2005-08-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal W...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003190-26 Sponsor Protocol Number: BUR03 Start Date*: 2020-12-21
    Sponsor Name:Julius-Maximilian University of Würzburg
    Full Title: An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER
    Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FGF...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10077957 X-linked hypophosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006121-65 Sponsor Protocol Number: 65411807 Start Date*: 2021-08-31
    Sponsor Name:Odense University Hospital
    Full Title: STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ...
    Medical condition: To investigate the effects of hydrocortisone replacement in participants with previous PMR and GCA, who are in GC-free remission and exhibit biochemical evidence of mild to moderate adrenal insuffi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001369 Adrenal insufficiency NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000469-19 Sponsor Protocol Number: BUR-CL207 Start Date*: 2020-11-03
    Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd.
    Full Title: A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Ag...
    Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burnett ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Prematurely Ended) SE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000600-29 Sponsor Protocol Number: UX023-CL301 Start Date*: 2016-09-15
    Sponsor Name:Ultragenyx Pharmaceuticals Inc
    Full Title: A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)
    Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, defective bone mineralisation, and impaired growth plate or endochondral ossification caused by inactivating mutations in t...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) IE (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003177-58 Sponsor Protocol Number: SPIOMET4HEALTH Start Date*: 2022-05-12
    Sponsor Name:Fundació Sant Joan de Déu (FSJD)
    Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO...
    Medical condition: Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005529-11 Sponsor Protocol Number: UX023-CL303 Start Date*: 2016-02-01
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) FR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 07 11:15:21 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA